医学
支气管肺发育不良
肺
先天性膈疝
重症监护医学
间充质干细胞
临床试验
呼吸窘迫
细胞疗法
干细胞
生物信息学
病理
外科
胎儿
内科学
怀孕
胎龄
遗传学
生物
标识
DOI:10.1016/j.semperi.2023.151724
摘要
Lung diseases are a main cause of mortality and morbidity in neonates. Despite major breakthroughs, therapies remain supportive and, in some instances, contribute to lung injury. Because the neonatal lung is still developing, the ideal therapy should be capable of preventing/repairing lung injury while at the same time, promoting lung growth. Cell-based therapies hold high hopes based on laboratory experiments in animal models of neonatal lung injury. Mesenchymal stromal cells and amnion epithelial cells are now in early phase clinical trials to test the feasibility, safety and early signs of efficacy in preterm infants at risk of developing bronchopulmonary dysplasia. Other cell-based therapies are being explored in experimental models of congenital diaphragmatic hernia and alveolar capillary dysplasia. This review will summarize current evidence that has lead to the clinical translation of cell-based therapies and highlights controversies and the numerous questions that remain to be addressed to harness the putative repair potential of cell-based therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI